| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 63 | 2024 | 866 | 7.990 |
Why?
|
| Kidney Tubules, Proximal | 50 | 2023 | 127 | 7.580 |
Why?
|
| Kidney | 75 | 2024 | 1498 | 6.410 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 28 | 2021 | 62 | 4.510 |
Why?
|
| Ischemia | 44 | 2015 | 421 | 4.410 |
Why?
|
| Albumins | 9 | 2023 | 120 | 3.160 |
Why?
|
| Glomerular Filtration Rate | 24 | 2024 | 745 | 3.140 |
Why?
|
| Nephrology | 13 | 2021 | 59 | 2.740 |
Why?
|
| Kidney Glomerulus | 15 | 2022 | 129 | 2.120 |
Why?
|
| Renal Insufficiency, Chronic | 9 | 2022 | 640 | 2.100 |
Why?
|
| Intravital Microscopy | 8 | 2023 | 23 | 2.050 |
Why?
|
| Actins | 22 | 2009 | 422 | 1.910 |
Why?
|
| Gentamicins | 16 | 2012 | 50 | 1.840 |
Why?
|
| Renal Circulation | 15 | 2015 | 75 | 1.690 |
Why?
|
| Rats | 77 | 2024 | 5586 | 1.680 |
Why?
|
| Albuminuria | 10 | 2022 | 190 | 1.610 |
Why?
|
| Plasma Volume | 5 | 2022 | 19 | 1.610 |
Why?
|
| Creatinine | 15 | 2021 | 511 | 1.590 |
Why?
|
| Fluorescent Dyes | 15 | 2020 | 340 | 1.370 |
Why?
|
| Cytoskeleton | 13 | 2004 | 180 | 1.340 |
Why?
|
| Endocytosis | 15 | 2023 | 170 | 1.310 |
Why?
|
| Diagnostic Imaging | 8 | 2014 | 340 | 1.300 |
Why?
|
| Animals | 132 | 2024 | 38106 | 1.170 |
Why?
|
| Adenosine Triphosphate | 13 | 2018 | 494 | 1.130 |
Why?
|
| Serum Albumin | 6 | 2020 | 147 | 1.110 |
Why?
|
| Kidney Diseases | 12 | 2021 | 428 | 1.090 |
Why?
|
| Rats, Sprague-Dawley | 40 | 2024 | 2537 | 1.090 |
Why?
|
| Kidney Function Tests | 5 | 2012 | 156 | 1.020 |
Why?
|
| Sepsis | 8 | 2018 | 669 | 0.980 |
Why?
|
| Microvilli | 16 | 2022 | 72 | 0.950 |
Why?
|
| Endothelium, Vascular | 8 | 2015 | 952 | 0.860 |
Why?
|
| Rats, Wistar | 14 | 2022 | 451 | 0.820 |
Why?
|
| Renal Insufficiency | 4 | 2023 | 173 | 0.800 |
Why?
|
| Microscopy, Fluorescence | 10 | 2020 | 404 | 0.800 |
Why?
|
| Dextrans | 5 | 2018 | 83 | 0.790 |
Why?
|
| Reperfusion Injury | 8 | 2024 | 300 | 0.790 |
Why?
|
| Clathrin | 2 | 2023 | 26 | 0.780 |
Why?
|
| Microscopy, Video | 4 | 2008 | 23 | 0.780 |
Why?
|
| Renal Dialysis | 9 | 2014 | 461 | 0.770 |
Why?
|
| Ureteral Obstruction | 2 | 2022 | 62 | 0.740 |
Why?
|
| Intra-Abdominal Hypertension | 1 | 2022 | 7 | 0.720 |
Why?
|
| Azotemia | 1 | 2022 | 13 | 0.710 |
Why?
|
| Receptors, Fc | 3 | 2020 | 54 | 0.700 |
Why?
|
| Career Choice | 3 | 2013 | 237 | 0.680 |
Why?
|
| Microscopy, Confocal | 8 | 2010 | 322 | 0.680 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2020 | 207 | 0.640 |
Why?
|
| Humans | 104 | 2024 | 146342 | 0.630 |
Why?
|
| Endothelial Cells | 4 | 2015 | 876 | 0.620 |
Why?
|
| Rhodamines | 2 | 2018 | 20 | 0.620 |
Why?
|
| Anti-Bacterial Agents | 10 | 2006 | 1942 | 0.610 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 1064 | 0.610 |
Why?
|
| LLC-PK1 Cells | 11 | 2006 | 18 | 0.610 |
Why?
|
| Bacterial Infections | 5 | 2018 | 247 | 0.590 |
Why?
|
| Indocyanine Green | 1 | 2019 | 43 | 0.570 |
Why?
|
| Critical Illness | 4 | 2018 | 908 | 0.550 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2019 | 165 | 0.550 |
Why?
|
| Fluorescein | 1 | 2018 | 23 | 0.540 |
Why?
|
| Microfilament Proteins | 5 | 2003 | 136 | 0.540 |
Why?
|
| Aminoglycosides | 5 | 2023 | 29 | 0.540 |
Why?
|
| Point-of-Care Systems | 2 | 2018 | 185 | 0.540 |
Why?
|
| RNA, Small Interfering | 4 | 2021 | 633 | 0.530 |
Why?
|
| Golgi Apparatus | 4 | 2006 | 99 | 0.520 |
Why?
|
| Cell Membrane | 17 | 2019 | 701 | 0.520 |
Why?
|
| Epithelium | 13 | 2020 | 295 | 0.520 |
Why?
|
| Actin Cytoskeleton | 4 | 2003 | 97 | 0.480 |
Why?
|
| Male | 79 | 2024 | 73396 | 0.460 |
Why?
|
| Xanthenes | 5 | 2013 | 10 | 0.440 |
Why?
|
| Cell Membrane Permeability | 2 | 2013 | 88 | 0.440 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2014 | 14 | 0.430 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 26 | 0.430 |
Why?
|
| Swine | 13 | 2011 | 821 | 0.430 |
Why?
|
| Metabolic Clearance Rate | 3 | 2013 | 115 | 0.430 |
Why?
|
| Mitochondria | 3 | 2018 | 997 | 0.430 |
Why?
|
| Actin Depolymerizing Factors | 5 | 2006 | 9 | 0.410 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 10 | 1995 | 55 | 0.410 |
Why?
|
| Biomarkers | 14 | 2022 | 4340 | 0.410 |
Why?
|
| Kidney Tubules, Distal | 3 | 2012 | 5 | 0.410 |
Why?
|
| Microvessels | 1 | 2015 | 98 | 0.390 |
Why?
|
| Photons | 5 | 2011 | 67 | 0.380 |
Why?
|
| Nephrons | 2 | 2011 | 23 | 0.370 |
Why?
|
| Biomedical Research | 7 | 2021 | 729 | 0.360 |
Why?
|
| Capillary Permeability | 5 | 2017 | 133 | 0.360 |
Why?
|
| Fellowships and Scholarships | 2 | 2013 | 355 | 0.350 |
Why?
|
| Optical Fibers | 1 | 2011 | 17 | 0.350 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2012 | 530 | 0.340 |
Why?
|
| Polysaccharides | 2 | 2021 | 88 | 0.330 |
Why?
|
| Image Enhancement | 2 | 2010 | 198 | 0.320 |
Why?
|
| Anemia | 2 | 2002 | 190 | 0.310 |
Why?
|
| Health Policy | 1 | 2013 | 399 | 0.310 |
Why?
|
| Antimycin A | 4 | 2003 | 14 | 0.310 |
Why?
|
| Biological Transport | 8 | 2022 | 424 | 0.300 |
Why?
|
| Time Factors | 19 | 2020 | 7109 | 0.300 |
Why?
|
| Cofilin 1 | 2 | 2009 | 5 | 0.300 |
Why?
|
| Tissue Distribution | 9 | 2024 | 334 | 0.300 |
Why?
|
| Kidney Cortex | 5 | 2014 | 27 | 0.300 |
Why?
|
| Kidney Tubules | 5 | 2020 | 117 | 0.300 |
Why?
|
| Precision Medicine | 1 | 2014 | 462 | 0.300 |
Why?
|
| Education, Medical, Graduate | 2 | 2013 | 568 | 0.300 |
Why?
|
| Microscopy | 3 | 2022 | 147 | 0.290 |
Why?
|
| Cell Line | 12 | 2018 | 2814 | 0.290 |
Why?
|
| Thrombomodulin | 1 | 2009 | 15 | 0.290 |
Why?
|
| Epithelial Cells | 6 | 2019 | 1119 | 0.280 |
Why?
|
| Microcirculation | 6 | 2010 | 142 | 0.280 |
Why?
|
| Membrane Lipids | 8 | 2001 | 81 | 0.280 |
Why?
|
| Disease Models, Animal | 13 | 2024 | 4580 | 0.280 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2009 | 55 | 0.280 |
Why?
|
| Receptors, Cell Surface | 3 | 2022 | 371 | 0.270 |
Why?
|
| Clathrin-Coated Vesicles | 1 | 2008 | 5 | 0.270 |
Why?
|
| beta 2-Microglobulin | 5 | 2009 | 47 | 0.270 |
Why?
|
| Fluorescein-5-isothiocyanate | 3 | 2017 | 34 | 0.270 |
Why?
|
| Luminescent Proteins | 3 | 2007 | 188 | 0.260 |
Why?
|
| Mice | 17 | 2024 | 18297 | 0.260 |
Why?
|
| Cell Polarity | 4 | 1998 | 138 | 0.260 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2008 | 152 | 0.250 |
Why?
|
| Folic Acid | 2 | 2009 | 197 | 0.250 |
Why?
|
| Rats, Inbred Strains | 12 | 2020 | 316 | 0.250 |
Why?
|
| Erythropoietin | 2 | 2012 | 100 | 0.240 |
Why?
|
| Cytokines | 3 | 2018 | 2081 | 0.240 |
Why?
|
| Klebsiella pneumoniae | 1 | 2006 | 48 | 0.240 |
Why?
|
| Phospholipids | 5 | 2001 | 215 | 0.240 |
Why?
|
| Cystatin C | 2 | 2021 | 65 | 0.230 |
Why?
|
| Diabetic Nephropathies | 3 | 2017 | 320 | 0.230 |
Why?
|
| Bacillus subtilis | 1 | 2006 | 67 | 0.230 |
Why?
|
| Microscopy, Polarization | 1 | 2005 | 30 | 0.230 |
Why?
|
| Injections, Intravenous | 4 | 2018 | 197 | 0.230 |
Why?
|
| Alpha-Globulins | 2 | 2024 | 20 | 0.230 |
Why?
|
| Physicians | 2 | 2011 | 955 | 0.220 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2010 | 778 | 0.220 |
Why?
|
| Iohexol | 2 | 2018 | 23 | 0.220 |
Why?
|
| Mass Screening | 1 | 2013 | 1307 | 0.220 |
Why?
|
| MicroRNAs | 1 | 2011 | 699 | 0.210 |
Why?
|
| Blood Coagulation | 3 | 2018 | 267 | 0.210 |
Why?
|
| Disease Progression | 7 | 2017 | 2867 | 0.210 |
Why?
|
| Adenoviridae | 4 | 2007 | 197 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 1408 | 0.210 |
Why?
|
| Kidney Failure, Chronic | 4 | 2011 | 589 | 0.210 |
Why?
|
| Inulin | 2 | 2017 | 12 | 0.210 |
Why?
|
| Protein C | 3 | 2009 | 54 | 0.200 |
Why?
|
| Tropomyosin | 1 | 2003 | 10 | 0.200 |
Why?
|
| Female | 25 | 2021 | 79499 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 1512 | 0.200 |
Why?
|
| Heart Failure | 3 | 2022 | 2329 | 0.200 |
Why?
|
| Secretory Vesicles | 1 | 2003 | 24 | 0.200 |
Why?
|
| Coloring Agents | 3 | 2019 | 88 | 0.200 |
Why?
|
| Endoplasmic Reticulum | 2 | 2003 | 268 | 0.200 |
Why?
|
| Sodium | 5 | 2009 | 196 | 0.190 |
Why?
|
| Liver | 2 | 2022 | 1864 | 0.190 |
Why?
|
| Models, Biological | 8 | 2014 | 1761 | 0.180 |
Why?
|
| Species Specificity | 1 | 2023 | 543 | 0.180 |
Why?
|
| Asparagine | 1 | 2022 | 34 | 0.180 |
Why?
|
| Cells, Cultured | 9 | 2019 | 4118 | 0.180 |
Why?
|
| Kinetics | 8 | 2008 | 1553 | 0.180 |
Why?
|
| Podocytes | 3 | 2020 | 80 | 0.180 |
Why?
|
| Destrin | 4 | 2003 | 4 | 0.180 |
Why?
|
| Nucleotides | 1 | 2002 | 128 | 0.170 |
Why?
|
| Membranes, Artificial | 4 | 1995 | 67 | 0.170 |
Why?
|
| Microscopy, Electron | 7 | 2007 | 384 | 0.170 |
Why?
|
| Protein Transport | 4 | 2010 | 443 | 0.170 |
Why?
|
| Heart | 2 | 2019 | 626 | 0.170 |
Why?
|
| Leukocytes | 4 | 2011 | 301 | 0.170 |
Why?
|
| Stress, Mechanical | 3 | 2019 | 497 | 0.170 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2002 | 345 | 0.170 |
Why?
|
| Hypertension | 2 | 2017 | 1272 | 0.170 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2020 | 6 | 0.160 |
Why?
|
| Academies and Institutes | 1 | 2021 | 61 | 0.160 |
Why?
|
| Gene Transfer Techniques | 4 | 2007 | 185 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2018 | 663 | 0.160 |
Why?
|
| Scattering, Small Angle | 2 | 2020 | 24 | 0.160 |
Why?
|
| Protein Synthesis Inhibitors | 2 | 2010 | 48 | 0.160 |
Why?
|
| Capillary Leak Syndrome | 1 | 2020 | 12 | 0.160 |
Why?
|
| Internship and Residency | 1 | 2011 | 1281 | 0.160 |
Why?
|
| X-Ray Diffraction | 2 | 2020 | 76 | 0.160 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2019 | 582 | 0.150 |
Why?
|
| Phosphorylation | 5 | 2014 | 1724 | 0.150 |
Why?
|
| Immunotoxins | 1 | 2020 | 51 | 0.150 |
Why?
|
| Myosins | 2 | 1997 | 131 | 0.150 |
Why?
|
| Solubility | 4 | 2009 | 240 | 0.150 |
Why?
|
| Sulfolobus solfataricus | 1 | 2019 | 9 | 0.150 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 120 | 0.150 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 69 | 0.150 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 177 | 0.150 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2002 | 449 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 2921 | 0.150 |
Why?
|
| Immunohistochemistry | 8 | 2012 | 1712 | 0.150 |
Why?
|
| Kidney Tubular Necrosis, Acute | 2 | 2009 | 26 | 0.150 |
Why?
|
| Archaeal Proteins | 1 | 2019 | 50 | 0.150 |
Why?
|
| Organizational Policy | 2 | 2009 | 76 | 0.140 |
Why?
|
| Conflict of Interest | 2 | 2009 | 55 | 0.140 |
Why?
|
| Basigin | 1 | 2018 | 24 | 0.140 |
Why?
|
| Prognosis | 2 | 2020 | 4351 | 0.140 |
Why?
|
| Nephritis | 1 | 2018 | 22 | 0.140 |
Why?
|
| Commerce | 2 | 2009 | 80 | 0.140 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2019 | 80 | 0.140 |
Why?
|
| Lipid A | 1 | 2018 | 27 | 0.140 |
Why?
|
| Intercellular Junctions | 4 | 1993 | 35 | 0.140 |
Why?
|
| Octoxynol | 4 | 2003 | 12 | 0.140 |
Why?
|
| International Cooperation | 4 | 2021 | 193 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2022 | 576 | 0.140 |
Why?
|
| Renal Reabsorption | 2 | 2017 | 4 | 0.130 |
Why?
|
| Alkaline Phosphatase | 1 | 2018 | 144 | 0.130 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-2 | 3 | 2014 | 6 | 0.130 |
Why?
|
| Sulfones | 2 | 1989 | 127 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2021 | 343 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 1 | 1999 | 180 | 0.130 |
Why?
|
| Immunoblotting | 3 | 2003 | 294 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2021 | 8123 | 0.130 |
Why?
|
| Recombinant Proteins | 4 | 2020 | 1361 | 0.130 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 4 | 2003 | 326 | 0.130 |
Why?
|
| Proteinuria | 4 | 2022 | 103 | 0.130 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 71 | 0.130 |
Why?
|
| Ischemic Preconditioning | 1 | 2018 | 47 | 0.130 |
Why?
|
| Endpoint Determination | 3 | 2012 | 84 | 0.130 |
Why?
|
| Fluid Therapy | 2 | 2017 | 154 | 0.130 |
Why?
|
| Lysosomes | 2 | 1998 | 134 | 0.130 |
Why?
|
| Proteins | 2 | 2001 | 1022 | 0.130 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2017 | 7 | 0.130 |
Why?
|
| Glycosylation | 3 | 2022 | 177 | 0.130 |
Why?
|
| DNA Repair | 1 | 2019 | 255 | 0.130 |
Why?
|
| Receptors, Vitronectin | 1 | 2017 | 5 | 0.130 |
Why?
|
| Models, Animal | 3 | 2019 | 387 | 0.130 |
Why?
|
| Fluoresceins | 1 | 2017 | 48 | 0.130 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2018 | 75 | 0.120 |
Why?
|
| Isotonic Solutions | 1 | 2017 | 43 | 0.120 |
Why?
|
| Spectrin | 1 | 1996 | 13 | 0.120 |
Why?
|
| Hydrodynamics | 1 | 2017 | 50 | 0.120 |
Why?
|
| Societies, Medical | 3 | 2010 | 907 | 0.120 |
Why?
|
| Renal Agents | 1 | 2016 | 5 | 0.120 |
Why?
|
| DNA Damage | 1 | 2019 | 439 | 0.120 |
Why?
|
| Oligosaccharides | 1 | 2017 | 62 | 0.120 |
Why?
|
| Optical Imaging | 1 | 2017 | 63 | 0.120 |
Why?
|
| Early Medical Intervention | 1 | 2017 | 59 | 0.120 |
Why?
|
| Green Fluorescent Proteins | 4 | 2006 | 408 | 0.120 |
Why?
|
| Renal Replacement Therapy | 5 | 2008 | 102 | 0.120 |
Why?
|
| Intracellular Membranes | 2 | 1994 | 76 | 0.120 |
Why?
|
| Apoptosis | 4 | 2009 | 2439 | 0.120 |
Why?
|
| Hemodynamics | 2 | 2015 | 1114 | 0.120 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 210 | 0.120 |
Why?
|
| Cricetulus | 1 | 2016 | 115 | 0.120 |
Why?
|
| United States | 6 | 2013 | 16136 | 0.110 |
Why?
|
| CHO Cells | 1 | 2016 | 167 | 0.110 |
Why?
|
| Cisplatin | 3 | 2009 | 347 | 0.110 |
Why?
|
| Polymers | 3 | 2002 | 488 | 0.110 |
Why?
|
| Dietary Proteins | 1 | 2017 | 135 | 0.110 |
Why?
|
| Cricetinae | 1 | 2016 | 296 | 0.110 |
Why?
|
| Pentoxifylline | 1 | 1995 | 23 | 0.110 |
Why?
|
| Chromatography, Liquid | 3 | 2022 | 453 | 0.110 |
Why?
|
| Lipopolysaccharides | 2 | 2010 | 861 | 0.110 |
Why?
|
| Fluorobenzenes | 1 | 2015 | 17 | 0.110 |
Why?
|
| Glycation End Products, Advanced | 1 | 2016 | 84 | 0.110 |
Why?
|
| Hemorheology | 1 | 2015 | 24 | 0.110 |
Why?
|
| Bacterial Proteins | 1 | 2001 | 980 | 0.110 |
Why?
|
| Heptanoic Acids | 1 | 2015 | 67 | 0.110 |
Why?
|
| Aged | 8 | 2021 | 26432 | 0.110 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2010 | 411 | 0.100 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2014 | 25 | 0.100 |
Why?
|
| Detergents | 3 | 2003 | 42 | 0.100 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2016 | 217 | 0.100 |
Why?
|
| Transcytosis | 1 | 2014 | 7 | 0.100 |
Why?
|
| Basement Membrane | 1 | 1994 | 33 | 0.100 |
Why?
|
| Interleukin-6 | 3 | 2009 | 784 | 0.100 |
Why?
|
| Capillaries | 1 | 2015 | 123 | 0.100 |
Why?
|
| Pericytes | 1 | 2014 | 42 | 0.100 |
Why?
|
| Cholesterol | 2 | 1987 | 411 | 0.100 |
Why?
|
| Genetic Vectors | 3 | 2018 | 327 | 0.100 |
Why?
|
| Endothelium | 1 | 2014 | 119 | 0.100 |
Why?
|
| Necrosis | 3 | 2003 | 243 | 0.100 |
Why?
|
| Patient Selection | 3 | 2012 | 728 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 6034 | 0.100 |
Why?
|
| Pyrroles | 1 | 2015 | 222 | 0.100 |
Why?
|
| Forecasting | 2 | 2015 | 388 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 1468 | 0.100 |
Why?
|
| Organizational Innovation | 1 | 2014 | 124 | 0.100 |
Why?
|
| Cell Adhesion | 3 | 2011 | 447 | 0.100 |
Why?
|
| Critical Care | 4 | 2016 | 706 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2015 | 219 | 0.100 |
Why?
|
| Machine Learning | 1 | 2019 | 594 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2017 | 1765 | 0.090 |
Why?
|
| Escherichia coli | 2 | 2008 | 832 | 0.090 |
Why?
|
| Double-Blind Method | 4 | 2021 | 2070 | 0.090 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2014 | 121 | 0.090 |
Why?
|
| Subcellular Fractions | 2 | 2006 | 73 | 0.090 |
Why?
|
| Escherichia coli Infections | 2 | 2011 | 125 | 0.090 |
Why?
|
| Algorithms | 3 | 2010 | 1849 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5439 | 0.090 |
Why?
|
| Middle Aged | 7 | 2019 | 36619 | 0.090 |
Why?
|
| NAD | 1 | 2012 | 80 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2021 | 295 | 0.090 |
Why?
|
| Contrast Media | 1 | 2015 | 493 | 0.090 |
Why?
|
| Punctures | 1 | 2012 | 40 | 0.090 |
Why?
|
| Adult | 8 | 2019 | 41087 | 0.090 |
Why?
|
| Aluminum | 2 | 1989 | 43 | 0.090 |
Why?
|
| Wounds and Injuries | 2 | 2012 | 959 | 0.090 |
Why?
|
| Membrane Potentials | 2 | 1989 | 278 | 0.090 |
Why?
|
| Up-Regulation | 2 | 2018 | 841 | 0.090 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2012 | 47 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 3416 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 901 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 2 | 2010 | 368 | 0.090 |
Why?
|
| Young Adult | 2 | 2019 | 14330 | 0.080 |
Why?
|
| Risk Factors | 7 | 2016 | 10921 | 0.080 |
Why?
|
| Foreign Medical Graduates | 1 | 2011 | 7 | 0.080 |
Why?
|
| Capitation Fee | 1 | 2011 | 14 | 0.080 |
Why?
|
| Radiometry | 1 | 2011 | 56 | 0.080 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2011 | 4 | 0.080 |
Why?
|
| Cell Communication | 2 | 2007 | 327 | 0.080 |
Why?
|
| Cell Movement | 2 | 2011 | 951 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2015 | 532 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2008 | 495 | 0.080 |
Why?
|
| Thorax | 1 | 2011 | 51 | 0.080 |
Why?
|
| Host-Pathogen Interactions | 2 | 2012 | 366 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2012 | 355 | 0.080 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2010 | 18 | 0.080 |
Why?
|
| Earthquakes | 1 | 2010 | 12 | 0.080 |
Why?
|
| Disaster Medicine | 1 | 2010 | 11 | 0.080 |
Why?
|
| Hospitalization | 1 | 2001 | 2475 | 0.080 |
Why?
|
| Endothelin-1 | 1 | 2012 | 177 | 0.080 |
Why?
|
| Nephrectomy | 2 | 2015 | 172 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2015 | 594 | 0.080 |
Why?
|
| Fimbriae, Bacterial | 1 | 2011 | 36 | 0.080 |
Why?
|
| Glutathione | 1 | 2012 | 369 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2014 | 509 | 0.080 |
Why?
|
| Reimbursement Mechanisms | 1 | 2011 | 79 | 0.080 |
Why?
|
| Kidney Transplantation | 2 | 2010 | 735 | 0.080 |
Why?
|
| Volunteers | 1 | 2010 | 40 | 0.080 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2013 | 208 | 0.080 |
Why?
|
| Population Dynamics | 1 | 2011 | 142 | 0.080 |
Why?
|
| Informed Consent | 1 | 2012 | 195 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2015 | 1298 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2013 | 404 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2010 | 2134 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3647 | 0.080 |
Why?
|
| Membrane Proteins | 4 | 2008 | 1130 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 2219 | 0.080 |
Why?
|
| Endosomes | 2 | 2004 | 139 | 0.080 |
Why?
|
| Transfection | 2 | 2018 | 916 | 0.080 |
Why?
|
| Nephrotic Syndrome | 2 | 2007 | 44 | 0.080 |
Why?
|
| Receptor, PAR-1 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Cytosol | 2 | 2003 | 215 | 0.080 |
Why?
|
| Dogs | 1 | 2011 | 517 | 0.080 |
Why?
|
| Mesoderm | 1 | 2010 | 147 | 0.080 |
Why?
|
| Equipment Design | 1 | 2011 | 520 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 610 | 0.070 |
Why?
|
| Biological Transport, Active | 2 | 2001 | 69 | 0.070 |
Why?
|
| Physician Assistants | 1 | 2011 | 102 | 0.070 |
Why?
|
| Delphi Technique | 2 | 2008 | 350 | 0.070 |
Why?
|
| Disease | 1 | 1990 | 97 | 0.070 |
Why?
|
| Disaster Planning | 1 | 2010 | 111 | 0.070 |
Why?
|
| Phosphoproteins | 2 | 2008 | 320 | 0.070 |
Why?
|
| Xenopus laevis | 2 | 2006 | 101 | 0.070 |
Why?
|
| Mentors | 1 | 2011 | 217 | 0.070 |
Why?
|
| Nurse Practitioners | 1 | 2011 | 141 | 0.070 |
Why?
|
| Regional Blood Flow | 2 | 2010 | 507 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2004 | 533 | 0.070 |
Why?
|
| Interleukin-1alpha | 1 | 2009 | 55 | 0.070 |
Why?
|
| Cystatins | 1 | 2008 | 7 | 0.070 |
Why?
|
| Deferoxamine | 1 | 1988 | 27 | 0.070 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2009 | 76 | 0.070 |
Why?
|
| Terminology as Topic | 2 | 2008 | 253 | 0.070 |
Why?
|
| Furosemide | 2 | 2021 | 37 | 0.070 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2008 | 42 | 0.070 |
Why?
|
| Vancomycin | 1 | 1989 | 96 | 0.070 |
Why?
|
| rho-Associated Kinases | 1 | 2009 | 77 | 0.070 |
Why?
|
| Reperfusion | 2 | 2002 | 53 | 0.070 |
Why?
|
| Acute Disease | 2 | 2008 | 1038 | 0.070 |
Why?
|
| Amides | 1 | 2009 | 100 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2113 | 0.070 |
Why?
|
| Perception | 1 | 2011 | 373 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 2623 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2015 | 228 | 0.070 |
Why?
|
| Receptors, Virus | 1 | 2008 | 91 | 0.070 |
Why?
|
| DNA Primers | 1 | 2009 | 487 | 0.070 |
Why?
|
| Lysine | 2 | 2020 | 303 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 335 | 0.070 |
Why?
|
| Polycystic Kidney Diseases | 2 | 2002 | 82 | 0.070 |
Why?
|
| Staining and Labeling | 3 | 2020 | 148 | 0.070 |
Why?
|
| Erythrocyte Aggregation | 1 | 2007 | 4 | 0.060 |
Why?
|
| Mucous Membrane | 1 | 2008 | 130 | 0.060 |
Why?
|
| Multiprotein Complexes | 1 | 2008 | 168 | 0.060 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2007 | 25 | 0.060 |
Why?
|
| Optics and Photonics | 1 | 2007 | 38 | 0.060 |
Why?
|
| Pyridinium Compounds | 1 | 2007 | 31 | 0.060 |
Why?
|
| Membrane Fluidity | 1 | 1987 | 8 | 0.060 |
Why?
|
| Ligation | 1 | 2007 | 88 | 0.060 |
Why?
|
| Interleukin-18 | 1 | 2008 | 234 | 0.060 |
Why?
|
| Stem Cells | 1 | 2011 | 613 | 0.060 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 45 | 0.060 |
Why?
|
| Artifacts | 1 | 2007 | 143 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 162 | 0.060 |
Why?
|
| Proteomics | 3 | 2022 | 1203 | 0.060 |
Why?
|
| Angiotensin II | 1 | 2007 | 102 | 0.060 |
Why?
|
| Interdisciplinary Communication | 1 | 2008 | 200 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2009 | 2219 | 0.060 |
Why?
|
| Computer Systems | 1 | 2006 | 54 | 0.060 |
Why?
|
| Lim Kinases | 1 | 2006 | 5 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2009 | 1224 | 0.060 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2006 | 23 | 0.060 |
Why?
|
| Bacteria | 1 | 2012 | 766 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2009 | 303 | 0.060 |
Why?
|
| Radiography | 1 | 2008 | 861 | 0.060 |
Why?
|
| Angiostatins | 1 | 2005 | 3 | 0.060 |
Why?
|
| Endostatins | 1 | 2005 | 10 | 0.060 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 172 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2010 | 2502 | 0.060 |
Why?
|
| Base Sequence | 1 | 2009 | 2123 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 371 | 0.050 |
Why?
|
| Plasma | 1 | 2007 | 222 | 0.050 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2021 | 198 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2018 | 335 | 0.050 |
Why?
|
| Biocompatible Materials | 1 | 1989 | 432 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2012 | 384 | 0.050 |
Why?
|
| Cation Transport Proteins | 1 | 2006 | 120 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2786 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2008 | 788 | 0.050 |
Why?
|
| Pyridines | 1 | 2009 | 610 | 0.050 |
Why?
|
| Iodine Radioisotopes | 2 | 1995 | 139 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 588 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2012 | 2791 | 0.050 |
Why?
|
| Leucine Zippers | 1 | 2003 | 13 | 0.050 |
Why?
|
| Cytochalasin D | 1 | 2003 | 4 | 0.050 |
Why?
|
| Thymosin | 1 | 2003 | 5 | 0.050 |
Why?
|
| Diet | 1 | 2012 | 1273 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 3926 | 0.050 |
Why?
|
| Gold | 2 | 1995 | 118 | 0.050 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 16 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2006 | 311 | 0.050 |
Why?
|
| Heme Oxygenase-1 | 1 | 2024 | 76 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 239 | 0.050 |
Why?
|
| Clone Cells | 2 | 1994 | 259 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2003 | 75 | 0.050 |
Why?
|
| Urine | 1 | 2003 | 63 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2009 | 996 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 947 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2005 | 303 | 0.050 |
Why?
|
| Pancreas | 1 | 2006 | 343 | 0.050 |
Why?
|
| Adherens Junctions | 1 | 2003 | 24 | 0.050 |
Why?
|
| Mannitol | 2 | 1994 | 42 | 0.050 |
Why?
|
| Adaptation, Physiological | 2 | 1997 | 568 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 120 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1982 | 0.050 |
Why?
|
| Xenopus | 1 | 2002 | 85 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2006 | 399 | 0.050 |
Why?
|
| von Willebrand Factor | 1 | 2003 | 84 | 0.050 |
Why?
|
| Angiography | 1 | 2003 | 206 | 0.050 |
Why?
|
| Microinjections | 1 | 2002 | 92 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 1219 | 0.050 |
Why?
|
| Skin | 1 | 2007 | 701 | 0.040 |
Why?
|
| Arterioles | 1 | 2002 | 52 | 0.040 |
Why?
|
| Phalloidine | 1 | 2001 | 3 | 0.040 |
Why?
|
| Rheology | 1 | 2002 | 94 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2003 | 268 | 0.040 |
Why?
|
| Stress Fibers | 1 | 2001 | 18 | 0.040 |
Why?
|
| Glucose | 1 | 1987 | 1053 | 0.040 |
Why?
|
| Reference Values | 2 | 1997 | 796 | 0.040 |
Why?
|
| Glycomics | 1 | 2021 | 7 | 0.040 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2002 | 124 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 1107 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2002 | 371 | 0.040 |
Why?
|
| Software | 1 | 2007 | 676 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2016 | 11821 | 0.040 |
Why?
|
| Sample Size | 2 | 2012 | 124 | 0.040 |
Why?
|
| Diuretics | 1 | 2021 | 66 | 0.040 |
Why?
|
| Membranes | 1 | 2001 | 13 | 0.040 |
Why?
|
| Cadherins | 1 | 2003 | 202 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2005 | 1177 | 0.040 |
Why?
|
| Scholarly Communication | 1 | 2021 | 4 | 0.040 |
Why?
|
| Video Recording | 1 | 2002 | 219 | 0.040 |
Why?
|
| Cell Hypoxia | 2 | 2018 | 249 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2002 | 391 | 0.040 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2006 | 584 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2012 | 279 | 0.040 |
Why?
|
| Indiana | 1 | 2021 | 38 | 0.040 |
Why?
|
| Sphingomyelins | 1 | 2001 | 22 | 0.040 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 25 | 0.040 |
Why?
|
| Solute Carrier Family 12, Member 1 | 1 | 2020 | 2 | 0.040 |
Why?
|
| Gene Expression | 1 | 2006 | 1463 | 0.040 |
Why?
|
| Myosin Type II | 1 | 2020 | 17 | 0.040 |
Why?
|
| Inflammation | 2 | 2003 | 2919 | 0.040 |
Why?
|
| Uromodulin | 1 | 2020 | 22 | 0.040 |
Why?
|
| Oxygen Consumption | 2 | 2018 | 721 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2020 | 58 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 426 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2021 | 96 | 0.040 |
Why?
|
| Renal Elimination | 1 | 2020 | 5 | 0.040 |
Why?
|
| Half-Life | 1 | 2020 | 157 | 0.040 |
Why?
|
| Aging | 1 | 2011 | 1996 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2003 | 560 | 0.040 |
Why?
|
| Protein Binding | 2 | 2020 | 2244 | 0.040 |
Why?
|
| Cell Fractionation | 2 | 1992 | 50 | 0.040 |
Why?
|
| Adolescent | 1 | 2019 | 22557 | 0.040 |
Why?
|
| Perfusion | 2 | 2011 | 255 | 0.040 |
Why?
|
| Shear Strength | 1 | 2019 | 73 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2002 | 584 | 0.040 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1999 | 109 | 0.040 |
Why?
|
| Urothelium | 1 | 1999 | 33 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 78 | 0.040 |
Why?
|
| Integrins | 1 | 1999 | 88 | 0.030 |
Why?
|
| alpha-MSH | 1 | 1998 | 6 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 1591 | 0.030 |
Why?
|
| Health | 1 | 1999 | 81 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2008 | 3712 | 0.030 |
Why?
|
| 3,3'-Diaminobenzidine | 1 | 1998 | 2 | 0.030 |
Why?
|
| 4-Chloro-7-nitrobenzofurazan | 1 | 1998 | 3 | 0.030 |
Why?
|
| Growth Substances | 1 | 1998 | 136 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 1998 | 9 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 972 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2001 | 394 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 165 | 0.030 |
Why?
|
| Internet | 1 | 2002 | 660 | 0.030 |
Why?
|
| Lung | 1 | 2011 | 4122 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2018 | 5246 | 0.030 |
Why?
|
| Heymann Nephritis Antigenic Complex | 1 | 1997 | 2 | 0.030 |
Why?
|
| Leucyl Aminopeptidase | 2 | 1988 | 2 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 1998 | 140 | 0.030 |
Why?
|
| Rats, Inbred Dahl | 1 | 2017 | 9 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2012 | 1135 | 0.030 |
Why?
|
| Methionine | 1 | 1998 | 160 | 0.030 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2017 | 31 | 0.030 |
Why?
|
| Ceramides | 1 | 1998 | 114 | 0.030 |
Why?
|
| Random Allocation | 1 | 2018 | 366 | 0.030 |
Why?
|
| Peptides | 1 | 2023 | 992 | 0.030 |
Why?
|
| Ankyrins | 1 | 1996 | 11 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 1997 | 100 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 212 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2000 | 1271 | 0.030 |
Why?
|
| Exocytosis | 1 | 1997 | 85 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 1997 | 208 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2012 | 1888 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2010 | 416 | 0.030 |
Why?
|
| Insulin | 1 | 2007 | 2525 | 0.030 |
Why?
|
| DNA | 1 | 2002 | 1421 | 0.030 |
Why?
|
| Program Development | 2 | 2008 | 371 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 508 | 0.030 |
Why?
|
| Cell Division | 1 | 1997 | 736 | 0.030 |
Why?
|
| Prevalence | 1 | 2002 | 2861 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2015 | 21 | 0.030 |
Why?
|
| South America | 1 | 2015 | 56 | 0.030 |
Why?
|
| Kidneys, Artificial | 1 | 1994 | 6 | 0.030 |
Why?
|
| Hematocrit | 1 | 2015 | 108 | 0.030 |
Why?
|
| Pyridones | 1 | 2016 | 210 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1133 | 0.030 |
Why?
|
| Urinary Tract Infections | 2 | 2007 | 209 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2014 | 38 | 0.030 |
Why?
|
| Ion Transport | 1 | 2014 | 61 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 115 | 0.030 |
Why?
|
| North America | 1 | 2015 | 300 | 0.030 |
Why?
|
| Models, Structural | 1 | 1993 | 40 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1995 | 405 | 0.030 |
Why?
|
| Paracrine Communication | 1 | 2014 | 67 | 0.020 |
Why?
|
| Europe | 1 | 2015 | 421 | 0.020 |
Why?
|
| Ferritins | 1 | 1994 | 69 | 0.020 |
Why?
|
| Proteome | 1 | 2018 | 520 | 0.020 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2013 | 10 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2014 | 179 | 0.020 |
Why?
|
| Potassium | 1 | 2014 | 151 | 0.020 |
Why?
|
| Tobramycin | 1 | 1994 | 63 | 0.020 |
Why?
|
| Acidosis | 1 | 1994 | 105 | 0.020 |
Why?
|
| Injections | 1 | 2014 | 201 | 0.020 |
Why?
|
| Blood Proteins | 1 | 1995 | 239 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2014 | 138 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 174 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2020 | 3125 | 0.020 |
Why?
|
| Neutrophils | 1 | 1999 | 1133 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 263 | 0.020 |
Why?
|
| Type C Phospholipases | 1 | 1993 | 69 | 0.020 |
Why?
|
| Phosphatidylinositols | 1 | 1993 | 59 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 1994 | 1041 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 352 | 0.020 |
Why?
|
| Bowman Capsule | 1 | 2012 | 1 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2014 | 759 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2012 | 70 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1996 | 728 | 0.020 |
Why?
|
| Ruthenium Red | 1 | 1991 | 7 | 0.020 |
Why?
|
| Egtazic Acid | 1 | 1991 | 37 | 0.020 |
Why?
|
| Permeability | 1 | 2012 | 166 | 0.020 |
Why?
|
| Electric Conductivity | 1 | 1991 | 86 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 195 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2012 | 144 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2011 | 128 | 0.020 |
Why?
|
| Fimbriae Proteins | 1 | 2011 | 25 | 0.020 |
Why?
|
| Haiti | 1 | 2010 | 13 | 0.020 |
Why?
|
| ADP-Ribosylation Factor 1 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2010 | 50 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2010 | 49 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1993 | 916 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2010 | 67 | 0.020 |
Why?
|
| Carcinogens | 1 | 2011 | 112 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 2022 | 0.020 |
Why?
|
| Transportation | 1 | 2010 | 54 | 0.020 |
Why?
|
| Bacterial Adhesion | 1 | 2011 | 109 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2010 | 64 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 1358 | 0.020 |
Why?
|
| Activated Protein C Resistance | 1 | 2009 | 3 | 0.020 |
Why?
|
| Citrates | 1 | 1989 | 41 | 0.020 |
Why?
|
| Sodium Isotopes | 1 | 2009 | 2 | 0.020 |
Why?
|
| Age Factors | 2 | 2008 | 3347 | 0.020 |
Why?
|
| Kidney Medulla | 1 | 2009 | 28 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 568 | 0.020 |
Why?
|
| Protective Agents | 1 | 2009 | 43 | 0.020 |
Why?
|
| Lipids | 1 | 2015 | 714 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2012 | 467 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 1989 | 103 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2010 | 178 | 0.020 |
Why?
|
| Hepcidins | 1 | 2009 | 20 | 0.020 |
Why?
|
| Acute-Phase Proteins | 1 | 2009 | 66 | 0.020 |
Why?
|
| Cellulose | 1 | 1989 | 55 | 0.020 |
Why?
|
| Lipocalins | 1 | 2009 | 35 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1989 | 77 | 0.020 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2008 | 17 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2008 | 11 | 0.020 |
Why?
|
| Lipocalin-2 | 1 | 2009 | 80 | 0.020 |
Why?
|
| Adenylyl Cyclases | 1 | 1988 | 60 | 0.020 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2009 | 81 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2011 | 385 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 1989 | 140 | 0.020 |
Why?
|
| Chemokines | 1 | 2009 | 217 | 0.020 |
Why?
|
| Blood Volume | 1 | 2008 | 57 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 545 | 0.020 |
Why?
|
| Developed Countries | 1 | 2008 | 38 | 0.020 |
Why?
|
| Phlorhizin | 1 | 1987 | 2 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 523 | 0.020 |
Why?
|
| Cimetidine | 1 | 2007 | 12 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 1992 | 650 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 471 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2007 | 53 | 0.020 |
Why?
|
| Filtration | 1 | 2007 | 68 | 0.020 |
Why?
|
| Proton-Translocating ATPases | 1 | 2007 | 5 | 0.020 |
Why?
|
| Cations | 1 | 2007 | 83 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2009 | 627 | 0.020 |
Why?
|
| Urea | 1 | 2007 | 84 | 0.020 |
Why?
|
| Renin-Angiotensin System | 1 | 2007 | 80 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2007 | 124 | 0.020 |
Why?
|
| Endotoxemia | 1 | 2007 | 85 | 0.010 |
Why?
|
| Risk | 1 | 2008 | 920 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1985 | 37 | 0.010 |
Why?
|
| Hexosaminidases | 1 | 1985 | 17 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2007 | 182 | 0.010 |
Why?
|
| Receptor, TIE-2 | 1 | 2005 | 11 | 0.010 |
Why?
|
| NADH Dehydrogenase | 1 | 1985 | 20 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 8391 | 0.010 |
Why?
|
| Peritonitis | 1 | 2006 | 82 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2007 | 216 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 616 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2005 | 57 | 0.010 |
Why?
|
| Laminin | 1 | 2005 | 72 | 0.010 |
Why?
|
| Developing Countries | 1 | 2008 | 312 | 0.010 |
Why?
|
| Succinate Dehydrogenase | 1 | 1985 | 65 | 0.010 |
Why?
|
| Xenopus Proteins | 1 | 2005 | 33 | 0.010 |
Why?
|
| Health Surveys | 1 | 2007 | 511 | 0.010 |
Why?
|
| Vesicular Transport Proteins | 1 | 2006 | 85 | 0.010 |
Why?
|
| Multiple Organ Failure | 1 | 2006 | 122 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 238 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2005 | 111 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 974 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2007 | 614 | 0.010 |
Why?
|
| Focus Groups | 1 | 2008 | 588 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 146 | 0.010 |
Why?
|
| Adsorption | 2 | 1995 | 154 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2011 | 1369 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 400 | 0.010 |
Why?
|
| Binding Sites | 1 | 2007 | 1309 | 0.010 |
Why?
|
| Neoplasms | 1 | 2020 | 2954 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2006 | 200 | 0.010 |
Why?
|
| Smoking | 1 | 2011 | 1486 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 287 | 0.010 |
Why?
|
| Communication | 1 | 2010 | 980 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 1987 | 874 | 0.010 |
Why?
|
| Vasodilation | 1 | 2007 | 519 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1987 | 533 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 778 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3034 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2003 | 42 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 113 | 0.010 |
Why?
|
| Propidium | 1 | 2002 | 8 | 0.010 |
Why?
|
| Fixatives | 1 | 2002 | 13 | 0.010 |
Why?
|
| Collagen | 1 | 2005 | 460 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 1665 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2001 | 17438 | 0.010 |
Why?
|
| Formaldehyde | 1 | 2002 | 66 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2007 | 883 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 617 | 0.010 |
Why?
|
| Medicare | 1 | 2006 | 920 | 0.010 |
Why?
|
| Sex Factors | 1 | 2006 | 2107 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2002 | 725 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 1998 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 2599 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 3545 | 0.010 |
Why?
|
| Child | 2 | 2008 | 22693 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1995 | 63 | 0.010 |
Why?
|
| Diffusion | 1 | 1995 | 119 | 0.010 |
Why?
|
| Amyloidosis | 1 | 1994 | 43 | 0.010 |
Why?
|
| Acrylic Resins | 1 | 1994 | 48 | 0.010 |
Why?
|
| Cattle | 1 | 1995 | 940 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 1997 | 1051 | 0.010 |
Why?
|
| Jejunum | 1 | 1989 | 36 | 0.000 |
Why?
|
| Citric Acid | 1 | 1989 | 33 | 0.000 |
Why?
|
| Duodenum | 1 | 1989 | 76 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1989 | 354 | 0.000 |
Why?
|